/
/
Clinical Trial: An Early Study with a New Immunomodulator (CC-220) With or Without Dex for Relapsed/Refractory Multiple Myeloma Patients
Clinical Trial: An Early Study with a New Immunomodulator (CC-220) With or Without Dex for Relapsed/Refractory Multiple Myeloma Patients image
Clinical Trial: An Early Study with a New Immunomodulator (CC-220) With or Without Dex for Relapsed/Refractory Multiple Myeloma Patients
Posted May 01, 2017

This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as a single therapy and in combination with dexamethasone. CC-220 is a new immunomodulator being developed by Celgene Corporation. The IMiDs are a backbone class of therapies for multiple myeloma. CD-220, also called iberdomide, affects the Cereblon pathway which is one of the mechanisms of action for the immunomodulator drugs. 

There are 3 active sites for this trial: The Mayo Clinic Scottsdale, the Karmanos Cancer Institute and at the Winship Cancer Institute.

Learn more and find the closest trial site here:

CC-220 Clinical Trial

To find all eligible clinical trials for your myeloma, click here: 

Find All Myeloma Clinical Trials

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811